Sepsis Trial of Early Physical Therapy Outside the ICU (STEP TO IT)

October 14, 2019 updated by: Jeffrey Rohde, University of Michigan

Sepsis Trial of Early Physical Therapy Outside the ICU: A Pilot Feasibility Study

The purpose of this study is to determine whether an additional physical therapy program can improve the mobility and functional outcomes of patients diagnosed with severe sepsis (an illness in which the body has a severe response to bacteria or other germs and develops worsened function of a major organ such as the kidneys, heart, or lungs).

Study Overview

Status

Terminated

Conditions

Detailed Description

Patients who are admitted to the hospitalist service at the University of Michigan Hospital will be screened for the presence of severe sepsis. Those who are deemed eligible and provide consent will be enrolled. Study patients will receive additional physical therapy according to a protocol developed for this study in addition to the usual care recommended by their regular treating physician. Additional treatments will be individualized based on enrolled patients' baseline physical function and progress and may include standing, stretching, transferring, and walking - either with assistance or independently. Treating therapists have been trained in the use of the protocol and individualization to maintain the highest standard of patient safety. Patients will be contacted 30 days after discharge to answer questions about their health and ability to perform routine tasks at home.

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Michigan
      • Ann Arbor, Michigan, United States, 48105
        • University of Michigan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Any English-speaking patient over the age of 18 who is currently admitted to a general care floor under the care of the Medicine Faculty Hospitalist Service at the University of Michigan Health System and has severe sepsis is eligible to take part in this study.

Exclusion Criteria:

  • Subjects must be deemed by the study team to give informed consent by being able to state the basic purpose of the study. Consent by a legally authorized representative (LAR) will not be sought.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Additional physical therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline ambulation
Time Frame: At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days. This outcome will be assessed at baseline and at each study protocol physical therapy session during the index hospitalization.
At day 0 (baseline enrollment) and for the duration of the participants' hospitalization, a predicted average length of stay of 5 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (iADLs)
Time Frame: At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)
Baseline ADLs will be assessed using chart review. 30 day follow-up ADL and iADL function will be assessed using a telephone survey
At day 0 (baseline enrollment) and day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days)
Discharge location
Time Frame: At day 5 (assessed at discharge; predicted average length of stay is 5 days)
The location of discharge (home, subacute rehabilitation facility, skilled nursing facility) will be assessed at discharge for all patients enrolled in the study.
At day 5 (assessed at discharge; predicted average length of stay is 5 days)
ICU Transfer Rate
Time Frame: Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.
The rate at which patients require transfer to the ICU will be assessed.
Participants will be followed for the duration of their hospitalization, an average length of stay of 5 days.
Length of stay
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
The length of stay will be recorded for patients enrolled in the trial.
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Employment status
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
For patients employed for pay prior to the index admission, employment status will be assessed by telephone survey 30 days post-discharge.
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Post-hospitalization physical function
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Patients' physical function will be assessed 30 days after discharge using the SF-10 instrument.
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Readmission
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
In-Hospital Mortality
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days
Falls
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Arrhythmia
Time Frame: During each study protocol physical therapy session while hospitalized
Clinically significant arrhythmias occurring during therapy sessions will be documented and recorded as a safety outcome.
During each study protocol physical therapy session while hospitalized
Pressure ulcers
Time Frame: Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
The presence and severity of pressure ulcers will be recorded.
Participants will be followed for the duration of their hospitalization, a predicted average length of stay of 5 days.
Cognitive function
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Enrolled patients' cognitive function will be assessed using the TICS-m instrument
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Depression
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
Patients will be screened for depression using the PHQ-2 instrument as part of the follow-up telephone survey.
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
30-Day Post-Hospitalization Mortality
Time Frame: At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).
At day 35 (assessed at 30 days post discharge; predicted average length of stay is 5 days).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrew Odden, MD, University of Michigan

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2014

Primary Completion (Actual)

September 1, 2019

Study Completion (Actual)

September 1, 2019

Study Registration Dates

First Submitted

May 22, 2014

First Submitted That Met QC Criteria

June 5, 2014

First Posted (Estimate)

June 9, 2014

Study Record Updates

Last Update Posted (Actual)

October 16, 2019

Last Update Submitted That Met QC Criteria

October 14, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • UM-HUM00073474

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on Additional physical therapy

3
Subscribe